Trial reportDrug design, development and therapy2025
Effect of Nebulized Dexmedetomidine on Postoperative Nausea and Vomiting in Female Patients Undergoing Radical Thoracoscopic Lung Cancer Resection: A Single-Center Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate the effect of nebulized dexmedetomidine on postoperative nausea and vomiting (PONV) in female patients undergoing radical thoracoscopic lung cancer resection. Patients and Methods: Patients were enrolled and randomized into the nebulized dexmedetomidine group (Dex group) and the normal saline group (NS group). The primary outcome was the overall incidence of PONV within 48 hours postoperatively. Secondary outcomes included the incidence and grade of PONV at multiple postoperative time points (T1: during PACU stay; T2: from PACU discharge to 8 hours postoperatively; T3: 8-16 hours postoperatively; T4: 16-24 hours postoperatively; T5: 24-32 hours postoperatively; T6: 32-40 hours postoperatively; T7: 40-48 hours postoperatively), postoperative sore throat (POST), Visual Analogue Scale (VAS) scores at the above time points, use of rescue analgesics and antiemetics, Quality of Recovery 15-item scale (QoR-15) scores et al. Results: A total of 64 eligible patients were enrolled, with 57 completing the study. There was no statistically significant difference in the overall incidence of PONV within 48 hours postoperatively between two groups. However, the incidence of PONV and POST in the Dex group was significantly lower than that in the NS group at T2. The area under the curve of VAS in the Dex group was significantly lower than that in the NS group within 24 hours and 48 hours postoperatively. The Dex group had a significantly lower rate of rescue analgesic use and higher postoperative QoR-15 scores within 48 hours postoperatively compared with the NS group. Conclusion: Nebulized inhalation of 1 μg/kg dexmedetomidine preoperatively can reduce the incidence of early postoperative PONV, enhance postoperative analgesia, alleviate postoperative sore throat, and improve postoperative recovery quality in female patients undergoing radical lung cancer surgery. Trial Number and Registry Url: Registration number, ChiCTR2400086070; https://www.chictr.org.cn/bin/project/edit?pid=235076.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.